Case Report
Copyright ©The Author(s) 2021.
World J Clin Cases. Sep 26, 2021; 9(27): 8177-8185
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8177
Table 1 Proportion of CD3+CD4-CD8 to 24 T-cell receptor variable β subfamilies in T-cells, with a significant increase in vβ14 (91.55%)
No
Name
Results
CD3+
Biological reference interval of CD3+CD4+
CD3+CD8+
Unit
1Vβ5.30.190.37-2.980.36-2.100.32-2.64%
2Vβ7.10.340.64-20.010.59-3.800.87-7.14%
3Vβ30.590.52-15.710.66-10.040.32-13.80%
4Vβ90.381.10-9.300.78-8.241.16-7.67%
5Vβ170.362.28-12.613.12-8.321.83-11.18%
6Vβ160.150.42-1.900.34-1.800.02-2.24%
7Vβ180.030.58-5.230.72-3.350.02-2.76%
8Vβ5.10.453.19-14.934.67-10.941.12-8.92%
9Vβ200.070-9.730.04-5.300.08-5.61%
10Vβ13.10.361.62-8.161.93-7.700.41-5.35%
11Vβ13.60.300.84-8.800.86-3.400.47-4.56%
12Vβ80.462.26-29.472.94-6.730.86-11.43%
13Vβ5.20.150.49-4.980.50-2.870.18-3.53%
14Vβ21.254.03-23.485.43-12.841.65-12.42%
15Vβ120.241-4.761.08-2.800.33-3.33%
16Vβ230.020.28-4.760.13-1.900.04-5.13%
17Vβ10.491.89-11.701.62-14.201.40-8.21%
18Vβ21.30.231.08-5.971.53-4.70.54-4.93%
19Vβ110.050.25-5.110.30-1.900.14-2.25%
20Vβ220.231.99-9.891.98-8.480.54-6.47%
21Vβ1491.551.33-8.031.57-4.681.50-14.3%
22Vβ13.20.390.80-5.280.72-7.270.96-9.62%
23Vβ40.040.79-3.261.20-2.830.61-4.34%
24Vβ7.20.060.05-5.450.00-3.100.01-12.10%
25The sum of the 24 subfamilies98.3869.9572.2566.58%
Table 2 Previously reported and current cases of classical metachronous Hodgkin lymphoma and peripheral T-cell lymphoma
Age, y/sex
One (EBV)
Therapy for one
Other (EBV)
Therapy for other
Interal (mo)
BM infiltration
Outcome
Ref.
32/MCHL (+)ABVDPTCL (-)Unknown24UnknownUnknownBrown et al[11], 2004
77/FPTCL (nd)CHOPCHL (nd)Radiation therapy48UnknownUnknownBrown et al[11], 2004
34/FCHL (?)ABVDPTCL (+)CHOP, IVE, intermediate-dose MTX, ASCT, BV47NoDied after 26 moMeconi et al[12], 2020
54/MCHL (nd)MOPP, ABVDPTCL (nd)Unknown24NoUnknownWlodarsk et al[13], 1993
76/FCHL (+)ABVDPTCL (+)CHOP108NoDied after 5 moOka et al[14], 2011
37/MPTCL (nd)IVAM, BEAM, ASCTCHL (+)ABVD60YesDied after 17 moPark et al[15], 2013
64/FCHL (-)ABVDPTCL (-)Etoposide, etc15YesDied after 9 moChang and Lee[16], 2015
59/MCHL (+)ABVD, PDL-1PTCL (-)E-CHOP, DICE, chidamide42YesDied after 7 moPresent study